SCHEMBL4157133

SCHEMBL4157133

O=C(NC1CCN(C(=O)O)CC1c1ccc(Cl)c(Cl)c1)c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 4/20 0.49
HSD11B1 P28845 1/20 0.46
SPTLC2 O15270 5/20 0.44
SLC6A12 P48065 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
MCHR1 Q99705 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
KDM1A O60341 1/20 0.42
KMT2A Q03164 2/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
TACR2 P21452 1/20 0.41
TACR1 P25103 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
MEN1 O00255 1/20 0.41
CCR1 P32246 1/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157136 1.00 SSTR3 (0.49) SSTR3HSD11B1SPTLC2SLC6A12TMEM97
SCHEMBL4153336 0.92 CHRNA7 (0.48) SPTLC2KMT2ADRD2DRD4TACR2
SCHEMBL4149849 0.92 CHRNA7 (0.48) SPTLC2KMT2ADRD2DRD4TACR2
SCHEMBL4141880 0.92 CHRNA7 (0.48) SPTLC2KMT2ADRD2DRD4TACR2
SCHEMBL4153226 0.90 TACR2 (0.51) SPTLC2DRD2DRD4TACR2TACR1
SCHEMBL4141180 0.90 TACR2 (0.49) SSTR3SPTLC2KMT2ATACR2TACR1
SCHEMBL4141183 0.90 TACR2 (0.49) SSTR3SPTLC2KMT2ATACR2TACR1
SCHEMBL4153052 0.90 TACR2 (0.49) SPTLC2KMT2ATACR2TACR1TAS1R3
SCHEMBL4153048 0.90 TACR2 (0.49) SPTLC2KMT2ATACR2TACR1TAS1R3
SCHEMBL4157300 0.88 CHRNA7 (0.46) SPTLC2DRD2DRD4TACR2TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470816-B2 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT SSTR3 45/4885HSD11B1 1023/4885SPTLC2 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.